Patients with nonvalvular atrial fibrillation who were prescribed apixaban vs rivaroxaban had a lower rate of ischemic stroke or systemic embolism and bleeding.
Topline results were announced from the phase 3 NODE-301 trial of etripamil nasal spray (Milestone Pharmaceuticals), a novel short-acting calcium channel blocker, being investigated for the at-home treatment of acute paroxysmal supraventricular tachycardia (PSVT).
A structural abnormality on cardiac magnetic resonance imaging may be a predictor of major adverse cardiac events in patients with nonsustained ventricular tachycardia and ventricular tachycardia/sudden cardiac death.
The Axis, Burden, Coupling interval, Ventricular Tachycardia risk score was found to accurately predict adverse left ventricular remodeling as well as subsequent adverse events in patients with frequent premature ventricular contractions.
The FDA has approved new dosing, monitoring, and evaluation recommendations for intravenous sotalol (Altathera), allowing for a reduction in hospital stay.
Researchers evaluated whether certain electrocardiogram parameters reflecting ventricular repolarization may help in identifying scleroderma in patients with increased risk for ventricular arrhythmias.
